<code id='E50FF8BEF8'></code><style id='E50FF8BEF8'></style>
    • <acronym id='E50FF8BEF8'></acronym>
      <center id='E50FF8BEF8'><center id='E50FF8BEF8'><tfoot id='E50FF8BEF8'></tfoot></center><abbr id='E50FF8BEF8'><dir id='E50FF8BEF8'><tfoot id='E50FF8BEF8'></tfoot><noframes id='E50FF8BEF8'>

    • <optgroup id='E50FF8BEF8'><strike id='E50FF8BEF8'><sup id='E50FF8BEF8'></sup></strike><code id='E50FF8BEF8'></code></optgroup>
        1. <b id='E50FF8BEF8'><label id='E50FF8BEF8'><select id='E50FF8BEF8'><dt id='E50FF8BEF8'><span id='E50FF8BEF8'></span></dt></select></label></b><u id='E50FF8BEF8'></u>
          <i id='E50FF8BEF8'><strike id='E50FF8BEF8'><tt id='E50FF8BEF8'><pre id='E50FF8BEF8'></pre></tt></strike></i>

          explore

          explore

          author:focus    Page View:9991
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Inaction leaves children at risk from dangerous chemotherapy drug
          Inaction leaves children at risk from dangerous chemotherapy drug

          EvangelineGallagher/TBIJAyearafteraninvestigationrevealedwidespreaduseofasubstandardcancerdrug,theWo

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          AI for drug discovery: Experts on separating hype from reality

          Fromleft:DaphneKoller,CEOofInsitro,VijayPandeofAndreessenHorowitzandscientistDerekLowespeakingatSTAT